Most in the biopharma industry would prefer to leave 2023 in the rearview mirror. Before we forge ahead, though, it’s valuable to reflect on how this challenging year closed out. 

Our 2023 Review covers the good, the bad and the ugly as we ask: Has the IPO window stayed firmly shut? Did venture capital fundraising see a dip? Was there an uptick in M&A activity in the final quarter? 

Find the answers to these questions and more. Download the report now for insights into the market's current condition and potential flickers of optimism for 2024.

KEY TAKEAWAYS

Three floating biotechs raised $617m in Q4
Two of them have seen share price growth
The IPO climate might improve in 2024
Keep an eye on obesity companies